Parkman Healthcare Partners LLC Cti Biopharma Corp Transaction History

Parkman Healthcare Partners LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$4.2 - $6.01 $1.45 Million - $2.07 Million	344,988 Added 24.49%	1,753,630 $7.37 Million
Q4 2022 Feb 13, 2023	BUY	$4.45 - $6.17 $883,311 - $1.22 Million	198,497 Added 16.4%	1,408,642 $8.47 Million
Q3 2022 Nov 14, 2022	BUY	$5.36 - $7.43 $852,765 - $1.18 Million	159,098 Added 15.14%	1,210,145 $7.04 Million
Q2 2022 Aug 12, 2022	BUY	$3.55 - $6.27 $2.93 Million - $5.18 Million	826,047 Added 367.13%	1,051,047 $6.28 Million
Q1 2022 May 13, 2022	BUY	$1.9 - $5.23 $427,500 - $1.18 Million	225,000 New	225,000 $1.05 Million

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Parkman Healthcare Partners LLC with notifications on news.